(3E,5E)-1-ACRYLOYL-3,5-BIS(4-NITROBENZYLIDENE)PIPERIDIN-4-ONE, 95%, 10mg

Ethyl 5-Bromovalerate>97.0%(GC)25g

4-METHYLAMINO-2,2,6,6-TETRAMETHYLPIPERIDINE, 95.0%, 25g

METHYL 1-(AMINOMETHYL)CYCLOPROPANECARBOXYLATE HCL, 95.0%, 50mg

1,10-Phenanthroline hydrate, 95.0%, 100g

1-(3-BROMOPHENYL)CYCLOBUTANECARBONITRILE, 95.0%, 1g

Ethyl 5-amino-1-(3-chlorophenyl)-1H-pyrazole-4-carboxylate, 95.0%, 1g

tert-Butyl 3-azabicyclo[3.2.0]heptan-1-ylcarbamate, 98%, 500mg

E-Plan fase EPLPHi S100x/1.25 objetivo IOS de inmersión en aceite con corrección infinita. Distancia de trabajo 0,36 mm

1-Methyl-4-nitro-3-propyl-1H-pyrazole-5-carboxylic acid, 95.0%, 100mg

Nitrato de manganeso(II) tetrahidratado, mínimo 98 %, pa, 500 g, envase de plástico.

3-Iodo-2-nitroaniline, 97%, 250mg

Benzamidine hydrochloride hydrate, 98.0%, 5g